secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-09-17T20:15:12+00:00
Accession:  0001193125-26-394360
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Faeth appoints co-founder Karen Vousden to board as Class II director
---------------------------------------------------------------------

- Board expanded from 5 to 6 directors; Vousden appointed effective Sept 11, 2026, serving until 2029 annual meeting.
- Vousden, 68, is a cancer biologist, co-founded Faeth in April 2019, and leads at Francis Crick Institute since 2017.
- Also appointed to Compensation Committee; receives standard director cash retainer and option for 25,000 shares under 2026 Equity Plan.
- Option vests monthly over 3 years, with full vesting upon change in control; no family or 404(a) transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/0001193125-26-394360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/d174402d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-394360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer